老王v.p.n5.2

老王v.p.n5.2

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

老王v.p.n5.2

Learn More
Folded page of a newspaper

老王v.p.n5.2

老王v.p.n5.2

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

老王v.p.n5.2

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

老王v.p.n5.2

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

老王v.p.n5.2

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

老王v.p.n5.2

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

老王v.p.n5.2

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

beehive加速器  快橙vnp官方版  蓝灯APP加速器 7.0.1  快橙vqn下载  老王加速最新版v2.2.16  vpn 旋风  xuanfeng加速器  老虎加速器下载